Palvella Therapeutics PVLA Interest Income (Expense), Operating

Interest Income (Expense), Operating at other companies

First BanCorpFBP

$220.96M+4.0%

PopularBPOP

$670.18M+10.7%

The BancorpTBBK

$88.81M-3.2%

DoubleVerify HoldingsDV

-$273K+8.7%

Morgan StanleyMS

$2.7B+14.9%

Quantum Computing Inc.QUBT

$13.5M+696%

Other financials

Income statement

See full

Revenue$53.0K-97.3%

Operating income-$14.9M-88.7%

Net income-$15.8M-92.6%

EPS (diluted)-$1.20-62.2%

Balance sheet

See full

Cash & equivalents$206.4M+173%

Total debt$584.0K—

Total equity$232.3M+318%

Total assets$263.8M+232%

Cash flow

See full

Operating cash flow-$10.9M-60.5%

CapEx--100%

Free cash flow-$2.7M+72.0%

Valuation

See full

Market cap$1.86B+468%

Profitability

See full

Operating margin-183.2%-13.5pp

Net margin71.7%+40.4pp

FCF margin-99.8%-34.2pp

Returns & leverage

See full

Return on equity-34.2%—

Debt / equity0×—

Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNet.

The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's interest income (expense), operating.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Palvella Therapeutics's interest income (expense), operating?: Palvella Therapeutics (PVLA) reported interest income (expense), operating of $1.07M in Q1 2026.
How has Palvella Therapeutics's interest income (expense), operating changed year-over-year?: Palvella Therapeutics's interest income (expense), operating increased by 42.7% year-over-year, from $752K to $1.07M.